PH-MODIFIED PECTIN (GCS-100)
Diffuse Large B-cell Lymphoma
La Jolla Pharmaceutical Companyother_biologicalPhase 1/2Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 73/ 100
Competitive context
271 Active assets in the Diffuse Large B-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 2/3 | A |
Evomela Ruijin Hospital | Phase 4 | BBB |
Axicabtagene Ciloleucel Ruijin Hospital | Phase 4 | BBB |
PREDNISONE TABLETS Beth Israel Deaconess Medical Center | Phase 4 | BBB |
Inno-206 Beth Israel Deaconess Medical Center | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
PH-MODIFIED PECTIN (GCS-100) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →